Has Ambarish Athavale, MD received payments from drug or device companies?

Yes. Drug and device makers reported $82,894 in general payments to Ambarish Athavale, MD across 137 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ambarish Athavale, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ambarish Athavale, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ambarish Athavale, MD

Nephrology · San Diego, CANPI 1255647145

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $58,436 of the $82,894 with a category attached, or 70.5%. 18 manufacturers reported payments, led by Omeros Corporation at 47.3% of the total. Reporting peaked in 2020 at $39,340 and has fallen 65.6% since, to $13,519 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$82,894in general payments, 2019–2025

Across 137 payments — averaging $605.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Omeros Corporation$39K
Calliditas Therapeutics US Inc.$16K
Aurinia Pharma U.S., Inc.$6K
Travere Therapeutics, Inc.$6K
Vertex$5K
Idorsia Pharmaceuticals US Inc$4K
plus $6K from 12 others

$42,341in research payments, 2019–2025

Across 9 payments — averaging $4704.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Omeros Corporation$42K

What the payments were for

Consulting fees$58,43670%
Speaking & faculty fees$15,20018%
Travel & lodging$3,9625%
Food & beverage$5,1556%
Education$1410%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Omeros Corporation	10	$39,232
Calliditas Therapeutics US Inc.	22	$15,792
Aurinia Pharma U.S., Inc.	6	$6,250
Travere Therapeutics, Inc.	40	$6,056
Vertex	6	$5,175
Idorsia Pharmaceuticals US Inc	3	$4,110
Novartis	5	$4,025
Otsuka America Pharmaceutical, Inc.	20	$885
Otsuka Pharmaceutical Development & Commercialization, Inc.	4	$385
AstraZeneca(2 entities)	10	$224
Amgen	2	$135
Nxstage Medical, Inc.	2	$134
Outset Medical Inc	1	$124
Genentech USA, Inc.	1	$120
Mallinckrodt Hospital Products Inc.	1	$113
Ardelyx, Inc.	1	$67
GSK	2	$42
ANI Pharmaceuticals, Inc.	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

narsoplimab$39,232
TARPEYO$15,206
LUPKYNIS$6,250
Tryvio$4,060
Fabhalta$3,851
Filspari$1,185
JYNARQUE$241
Rituxan$120
NXSTAGE SYSTEM ONE$114
ACTHAR$113

How this compares

$82,894 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California →

Medicare billing

Part B allowed, 2024

$179,086

Medicare patients

298

Services billed

1,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	49	$77,720
RenvelaSevelamer Carbonate	15	$24,469
VeltassaPatiromer Calcium Sorbitex	17	$17,166
Sevelamer Carbonate	33	$9,517
Bumetanide	26	$1,444
Calcitriol	23	$566
Albuterol Sulfate HfaAlbuterol Sulfate	12	$546
Losartan Potassium	53	$412
Nifedipine ErNifedipine	11	$374
Carvedilol	15	$271
Chlorthalidone	17	$262
Tamsulosin Hcl	19	$245
Furosemide	36	$242
Potassium Chloride	16	$181
Amlodipine Besylate	35	$139

Paid to pharmacies, not to this prescriber.

Other nephrology in San Diego

Ravindra MehtaSan Diego$184K
Juan QuevedoSan Diego$53K
Anjay RastogiLos Angeles$2.2M
Glenn ChertowStanford$2M
Luis AlvarezPalo Alto$1.8M
Jose MorfinSacramento$1M
Rodolfo BatarseRancho Mirage$910K
Vandana MathurWoodside$769K
Yasir QaziOrange$618K
Rafael VillicanaLoma Linda$610K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →